Enanta Pharmaceuticals (NASDAQ: ENTA) share price rises 15.8% following analyst upgrade


Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) climbed 15.8% in Wednesday’s session after Oppenheimer raised its price target on the share from $ 55.00 to $ 73.00. Oppenheimer currently has a market performance rating on the stock. Enanta Pharmaceuticals traded at $ 87.03 and last traded at $ 87.03. 141 shares were traded during trading, a decrease of 100% from the average session volume of 152,208 shares. The stock had previously closed at $ 75.18.

Other analysts have also recently published research reports on the company. Jefferies Financial Group began covering Enanta Pharmaceuticals in a research report on Wednesday, October 6. They issued a “buy” note and a target price of $ 95.00 for the company. Royal Bank of Canada lowered its price target for Enanta Pharmaceuticals from $ 74.00 to $ 72.00 and set a “sector performance” rating for the company in a research report released on Friday, November 19. Roth Capital lowered its price target on Enanta Pharmaceuticals from $ 107.00 to $ 101.00 and set a “buy” rating for the company in a research report released Tuesday. Robert W. Baird increased his target price on Enanta Pharmaceuticals from $ 71.00 to $ 130.00 and gave the stock an “outperformance” rating in a research report published on Monday, November 8. Ultimately, Zacks investment research downgraded Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report released on Wednesday, November 10. Five equity research analysts rated the stock with a conservation rating and four gave the company a buy rating. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $ 89.56.

In related news, VP Nathalie Adda sold 4,047 shares of the company in a transaction that took place on Monday, October 11. The stock was sold for an average price of $ 70.34, for a total trade of $ 284,665.98. The sale was disclosed in a file with the Securities & Exchange Commission, which is available at this link. Also, CEO Jay R. Luly sold 4,516 shares of the company in a transaction that took place on Wednesday, September 15. The shares were sold at an average price of $ 59.06, for a total value of $ 266,714.96. Disclosure of this sale can be found here. Insiders sold 31,563 shares of the company valued at $ 2,304,747 during the last quarter. Company insiders own 11.74% of the company’s shares.

(A d)

The government’s cash injection could cause lithium exploration companies to skyrocket. They desperately need new lithium mines to end China’s lithium monopoly. See how you could profit from this huge injection of money.

A number of hedge funds have recently changed their holdings of stocks. Bank of New York Mellon Corp increased its stake in Enanta Pharmaceuticals by 4.0% in the third quarter. Bank of New York Mellon Corp now owns 183,342 shares of the biotech company valued at $ 10,416,000 after purchasing an additional 6,969 shares during the period. BNP Paribas Arbitrage SA increased its stake in Enanta Pharmaceuticals by 150.9% in the third quarter. BNP Paribas Arbitrage SA now owns 18,834 shares of the biotechnology company valued at $ 1,070,000 after purchasing an additional 11,326 shares during the period. Two Sigma Advisers LP increased its stake in Enanta Pharmaceuticals by 8.3% in the third quarter. Two Sigma Advisers LP now owns 81,800 shares of the biotech company valued at $ 4,647,000 after purchasing an additional 6,300 shares during the period. UBS Group AG increased its stake in Enanta Pharmaceuticals by 183.3% in the third quarter. UBS Group AG now owns 31,205 shares of the biotech company valued at $ 1,772,000 after purchasing an additional 20,191 shares during the period. Finally, Voloridge Investment Management LLC purchased a new stake in Enanta Pharmaceuticals in the third quarter valued at $ 691,000. 93.02% of the shares are currently held by institutional investors.

The company has a market cap of $ 1.76 billion, a PE ratio of -20.93 and a beta of 0.63. The company has a 50-day moving average of $ 72.79 and a two-hundred-day moving average of $ 56.52.

Enanta Pharmaceuticals (NASDAQ: ENTA) last released its results on Monday, November 22. The biotech company reported ($ 1.22) EPS for the quarter, beating analyst consensus estimates of ($ 1.31) by $ 0.09. Enanta Pharmaceuticals recorded a negative return on equity of 14.86% and a negative net margin of 86.21%. During the same period of the previous year, the company made EPS ($ 0.55). As a group, sell-side analysts expect Enanta Pharmaceuticals, Inc. to post EPS of -4.01 for the current fiscal year.

Enanta Pharmaceuticals Company Profile (NASDAQ: ENTA)

Enanta Pharmaceuticals, Inc. is a biotechnology company dedicated to the discovery and development of small molecule drugs for the treatment of viral infections and liver disease. It produces clinical candidates that target respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH) diseases.

Featured article: What does it mean to own a share in the name of a street?

This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Enanta Pharmaceuticals now?

Before you consider Enanta Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and Enanta Pharmaceuticals was not on the list.

While Enanta Pharmaceuticals currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here


Comments are closed.